| Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: A randomised, double-blind, hypothesis-generating study. | |
| | |
MedLine Citation:
|
PMID: 23404447 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Cytomegalovirus is highly prevalent in glioblastomas. In 2006, we initiated a randomized, double-blind, placebo-controlled, hypothesis-generating study to examine the safety and potential efficacy of Valganciclovir as an add-on therapy for glioblastoma. Forty-two glioblastoma patients were randomized in double-blind fashion to receive Valganciclovir or placebo in addition to standard therapy for 6 months. Magnetic resonance images were obtained before and immediately and 3 and 6 months after surgery to evaluate treatment efficacy by measuring contrast enhancing tumour volume (primary end point). Survival data were analysed for patients and controls in explorative analyses to aid the design of future randomised trials. Trends but no significant differences were observed in tumour volumes in Valganciclovir and placebo patients at 3 (3.58 vs 7.44 cm(3) , respectively, P = 0.2881) and 6 (3.31 vs 13.75 cm(3) , P = 0.2120) months. Median overall survival (OS) was similar in both groups (17.9 vs 17.4 months, P = 0.430). Patients could take Valganciclovir for compassionate use after the study phase. Explorative analyses showed an OS of 24.1 months (95% CI, 17.4-40.3) in patients receiving >6 months of Valganciclovir (Val>6M) versus 13.1 months (95% CI, 7.9-17.7, P<0.0001) in patients receiving Valganciclovir for 0 or <6 months, and 13.7 months (95% CI, 6.9-17.3, P = 0.0031) in contemporary controls. OS at 4 years was 27.3% in Val>6M patients versus 5.9% in controls (P = 0.0466). Prolonged OS in Val>6M patients suggest that future randomised trials are warranted and should evaluate whether continuous antiviral treatment can improve outcome in glioblastoma patients. © 2013 Wiley Periodicals, Inc. |
| | |
Authors:
|
Giuseppe Stragliotto; Afsar Rahbar; Nina Wolmer Solberg; Anders Lilja; Chato Taher; Abiel Orrego; Birgitta Bjurman; Charlotte Tammik; Petra Skarman; Inti Peredo; Cecilia Söderberg-Nauclér |
Related Documents
:
|
22136877 - Salmeterol or doxycycline do not inhibit acute bronchospasm and airway inflammation in ... 15776397 - Long-term results of above knee femoro-popliteal bypass depend on indication for surger... 8760987 - Angioscopically-assisted in situ saphenous vein bypass for infrainguinal revascularisat... 16689977 - Complex bypasses and fistulas for difficult hemodialysis access: a prospective, single-... 20061517 - Preoperative systolic strain rate predicts postoperative left ventricular dysfunction i... 1361797 - Treatment of staphylococcus aureus nasal carriers in capd with mupirocin. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-2-13 |
Journal Detail:
|
Title: International journal of cancer. Journal international du cancer Volume: - ISSN: 1097-0215 ISO Abbreviation: Int. J. Cancer Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-2-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0042124 Medline TA: Int J Cancer Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2013 UICC. |
Affiliation:
|
Departments of Neurology, Center for Molecular Medicine, L8:03, Karolinska Institute, 171 76 Stockholm, Sweden. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The impact of metabolic control and QTc prolongation on all-cause mortality in patients with type 2 ...
Next Document: Morphological Quantitative Criteria and Aesthetic Evaluation of Eight Female Han Face Types.